Skip to main content
    L

    Lifestance Health Group Inc (LFST)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $14.48
    +0.40 (+2.84%)

    Market Cap: $5.35B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Lifestance Health Group Inc (LFST) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Lifestance Health Group reported EPS of $0.06, above the $0.03 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(10/21)
    Avg Surprise
    +27.91%
    Streak
    4 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.04
    Range$0.02 - $0.06
    13 analysts
    Revenue Consensus
    $462.39M
    Range$433.95M - $483.64M
    11 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.10
    Range$0.09 - $0.11
    2 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.10-0.5%
    60d ago$0.10-0.5%
    30d ago$0.10-0.5%
    7d ago$0.10-0.5%
    Current$0.10
    Revenue Consensus
    $462.50M
    Range$457.25M - $466.61M
    3 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 55.6% below the $0.09 reported for the quarter ended Dec 31, 2025.

    LFST's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    LFST Earnings Call

    The latest LFST earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, LFST beat 10, missed 8 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $455.86M, up 25.3% from $363.81M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.06$0.03N/A+100.00%Beat+500.0%50 up, 1 downNov 5, 2026$455.86M
    Jun 30, 2026$0.06$0.03N/A+100.00%BeatN/A54 up, 0 downAug 6, 2026$435.35M
    Mar 31, 2026$0.07$0.06$0.06 - $0.06+16.67%Beat+40.0%42 up, 0 downMay 7, 2026$403.48M
    Dec 31, 2025$0.09$0.05$0.05 - $0.06+64.38%BeatN/A31 up, 0 downFeb 25, 2026$382.19M
    Sep 30, 2025$0.01$0.04$0.04 - $0.04-75.00%Miss-66.7%11 up, 0 downNov 6, 2025$363.81M
    Jun 30, 2025-$0.01-$0.03N/A+66.67%Beat-200.0%11 up, 0 downAug 7, 2025$345.31M
    Mar 31, 2025$0.05$0.01$0.01 - $0.01+400.00%BeatN/A11 up, 0 downMay 7, 2025$332.97M
    Dec 31, 2024-$0.01-$0.04N/A+73.89%BeatN/A11 up, 0 downFeb 27, 2025$325.48M
    Sep 30, 2024$0.03-$0.01N/A+400.00%BeatN/A70 up, 0 downNov 7, 2024$312.72M
    Jun 30, 2024$0.01-$0.01N/A+200.00%BeatN/A50 up, 0 downAug 8, 2024$312.33M
    Mar 31, 2024-$0.06-$0.01N/A-500.00%MissN/A50 up, 0 downMay 9, 2024$300.44M
    Dec 31, 2023-$0.12-$0.09-$0.14 - -$0.07-33.33%MissN/A70 up, 0 downFeb 28, 2024$280.60M
    Sep 30, 2023-$0.02-$0.02N/A0.00%In lineN/A50 up, 0 downNov 8, 2023$262.89M
    Jun 30, 2023-$0.03-$0.02N/A-50.00%MissN/A60 up, 0 downAug 9, 2023$259.58M
    Mar 31, 2023-$0.03-$0.03N/A0.00%In lineN/A40 up, 0 downMay 10, 2023$252.59M
    Dec 31, 2022-$0.13-$0.13-$0.16 - -$0.110.00%In lineN/A61 up, 0 downMar 8, 2023$229.36M
    Sep 30, 2022-$0.02-$0.01N/A-100.00%MissN/A60 up, 0 downNov 8, 2022$217.56M
    Jun 30, 2022-$0.03-$0.02-$0.19 - -$0.02-50.00%MissN/A60 up, 0 downAug 9, 2022$209.53M
    Mar 31, 2022-$0.02-$0.04-$0.25 - -$0.04+50.00%BeatN/A52 up, 0 downMay 9, 2022$203.09M
    Dec 31, 2021-$0.33-$0.21-$0.37 - -$0.03-57.14%MissN/A6N/AMar 10, 2022$190.00M
    Sep 30, 2021-$0.35-$0.02-$0.37 - -$0.01N/AN/AN/A7N/ANov 8, 2021$173.84M
    Jun 30, 2021-$0.06-$0.05N/A-20.00%MissN/A3N/AAug 11, 2021$160.55M
    Mar 31, 2021-$0.10N/AN/AN/AN/AN/AN/AN/AApr 12, 2021$143.13M
    Dec 31, 2020-$0.04N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$118.12M
    Last 24 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.14, a profit after a loss of $0.03 per share the year before. It was -$0.04 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.14N/A
    Dec 31, 2024-$0.03N/A
    Dec 31, 2023-$0.20N/A
    Dec 31, 2022-$0.20N/A
    Dec 31, 2021-$0.84N/A
    Dec 31, 2020-$0.04N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,35013
    2026Q2Jun 30, 20266,36014
    2026Q1Mar 31, 20264,72013
    2025Q4Dec 31, 20257,47515
    2025Q3Sep 30, 20255,42912
    2025Q2Jun 30, 20255,52413
    2025Q1Mar 31, 20255,15611
    2024Q4Dec 31, 20245,2829

    2026Q3 Earnings Call

    Opening remarks

    Monica Prokocki VP of Finance and Investor Relations Thank you, operator. Good morning, everyone, and welcome to LifeStance Health's third quarter 2026 earnings conference call. I'm Monica Prokocki, Vice President of Finance and Investor Relations. Joining me today are Dave Bourdon, Chief Executive Officer; and Ryan McGroarty, Chief Financial Officer. We issued the earnings release and presentation before the market opened this morning. Both are available on the Investor Relations section of our website, investor.lifestance.com. In addition, a replay will be available following the call. Before turning over to management for their prepared remarks, please direct your attention to the disclaimers about forward-looking statements included in the earnings press release and SEC filings. Today's remarks contain forward-looking statements, including statements about our financial performance outlook, business model and strategy. Those statements involve risks, uncertainties and other factors, as noted in our periodic filings with the SEC, that could cause actual results to differ materially. Please note that we report results using non-GAAP financial measures, which we believe provide additional information for investors to help facilitate comparison of current and past performance. A reconciliation to the most directly comparable GAAP measures is included in the earnings press release tables and presentation appendix. Unless otherwise noted, all results are compared to the comparable period in the prior year. At this time, I'll turn the call over to Dave Bourdon, CEO of LifeStance. Dave?

    David Bourdon CEO Thanks, Monica, and thank you all for joining us today. This was a tremendous quarter for LifeStance with momentum across all areas of the business. For the second consecutive quarter, we had revenue growth of 25% or more and adjusted EBITDA margins of 15%. We are once again raising our full-year guidance across all metrics, reflecting our confidence in the trajectory of the business. Ryan will provide additional detail on our updated outlook shortly. We continue to make great progress in increasing access to high-quality, affordable mental health care, growing our clinician base to more than 8,800 as the value proposition continues to resonate. Clinician productivity also remains very strong, building on last year's improvements and underscoring the strength and scalability of LifeStance's model. Turning to technology. We continue to deploy digital tools, AI capabilities and workflow automation to improve patient access, enhance the clinician experience and drive greater efficiency across the organization. Regarding the EHR, we are making progress in preparing for the transition to the new vendor, which will occur throughout next year. We are advancing readiness efforts through workflow improvement and change management planning, positioning us for a successful phased rollout while minimizing disruption to clinicians and patients. In regard to geographic expansion, we remain excited about the significant opportunity to increase density in existing markets while also expanding into new geographies.

    Frequently Asked Questions About LFST

    Did LFST beat earnings estimates last quarter?

    Yes. Lifestance Health Group reported EPS of $0.06 for the quarter ended Sep 30, 2026, above the $0.03 estimate, a 100.00% surprise.

    What EPS do analysts expect from LFST next quarter?

    The consensus EPS estimate for Lifestance Health Group for the quarter ending Dec 31, 2026 is $0.04 from 13 analysts, with estimates from $0.02 to $0.06.

    How often does LFST beat earnings estimates?

    Lifestance Health Group beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +93.33%.